OncoMatch/Multiple Myeloma (MM)/NRAS
Multiple Myeloma (MM)NRAS Clinical Trials
1 recruiting trials·Updated daily from ClinicalTrials.gov
NRAS mutations occur in approximately 20% of multiple myeloma and, together with KRAS mutations, represent the most frequent RAS pathway activations in this disease. NRAS-mutant myeloma activates MEK/ERK signaling, which may be targetable with MEK inhibitors. Trials explore MEK inhibitor combinations with IMiDs or proteasome inhibitors and novel RAS-directed strategies in NRAS-mutant myeloma.
Top recruiting
Top recruiting NRAS Multiple Myeloma (MM) trials
Ranked by phase and US site count. See all 1 trials matched to your profile →
Other Multiple Myeloma (MM) biomarkers
Browse other molecular targets with active Multiple Myeloma (MM) trials.